Providing patients and customers with
uncompromising quality and value for almost 40 years

Par is a specialty pharmaceutical company that develops, manufacture and markets innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par Pharmaceutical offers a line of high barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.

At Par, our most important resource is the talent and dedication of our nearly 1,900 employees, each of whom is part of a culture that values integrity, customer focus, teamwork and performance. In creating a climate that encourages collaboration, Par has become the partner of choice within its industry and has built a diverse network of strategic partnerships with dozens of companies. Headquartered in Woodcliff Lake, New Jersey, Par has manufacturing and R&D facilities in Chestnut Ridge, New York, Irvine, California, Rochester, Michigan, Stratford, Connecticut and Chennai, India.

Recent News

05/27/15Par Pharmaceutical Receives Favorable Appeals Court Ruling in Generic Exelon® Patch Litigation
Chestnut Ridge, NY, May 27, 2015 – Par Pharmaceutical Companies, Inc. today announced that the United States Court of Appeals for the Federal Circuit has upheld the U.S. District Court for the District of Delaware’s earlier ruling that Par’s filing of an Abbreviated New Drug Application for its generic version of Novartis’ Exelon® Patch (rivastigmine transdermal system) does not infringe United States Patent Nos. 6,316,023 or 6,335,031.  The appeals court also affirmed the district court’s ... 
05/26/15Par Specialty Pharmaceuticals Launches Cortisporin®-TC Otic Suspension
CHESTNUT RIDGE, N.Y., May 26, 2015 /PRNewswire/ -- Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin®-TC Otic Suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension).  Cortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal (otitis externa), caused by organisms susceptible to the action of the antibiotics; ... 
05/18/15Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader
- Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for future growth and further strategic M&A - Creates specialty pharmaceutical company with one of industry’s fastest growing generics businesses and expanded product portfolio, pipeline, technology platform and manufacturing capabilities - Positions Endo for long-term double-digit organic growth, strong cash flow and financial flexibility - Accretive to non-GAAP diluted earnings per share within... 
05/07/15Par Pharmaceutical Announces First Quarter 2015 Conference Call
Chestnut Ridge, NY, May 7, 2015 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, May 13, 2015 at 10:00 a.m. EDT to review its results of operations for the first quarter ended March 31, 2015.  Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission and will make certain other information available on its website by following the instruction... 

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.